Market research
4591.TSE Ribomic Inc
TSE JPY Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 4B
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 0.27
Profile
Company facts
- Exchange
- TSE
- Currency
- JPY
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- JP3974850004
- Market cap
- 4B
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- Not available
- Beta
- 0.27
About
About Ribomic Inc
Ribomic Inc. engages in the discovery and development of pharmaceutical compounds using RNA aptamers in Japan and Europe. The company develops RBM-007, which is in Phase III clinical trial for the treatment of achondroplasia; Phase II clinical trial for the treatment of wet age-related macular degeneration; and pre-clinical trial for the treatment of diabetic macular edema. It is also involved in the development of drugs in pre-clinical trial stage, including RBM-006 for the treatment of retinal disease, proliferative, vitreoretinopathy, glaucoma, and diabetic retinopathy; RBM-011 for the treatment of pulmonary arterial hypertension; RBM-003 for the treatment of heart failure; RBM-010 for the treatment of osteoarthritis; and RBM-009 for the treatment of severe asthma, as well as RBM-101, which is in discovery stage for the affinity purification of human IgG and Fc-fusion proteins. The company was incorporated in 2003 and is headquartered in Minato, Japan.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the 4591.TSE discussion.
5 years, 6 months ago
Ribomic Inc is currently in a long term downtrend where the price is trading 14.6% below its 200 day moving average.
From a valuation standpoint, the stock is 17.8% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 83.1.
Ribomic Inc's total revenue sank by 2.6% to $2M since the same quarter in the previous year.
Its net income has dropped by 4.7% to $-265M since the same quarter in the previous year.
Based on the above factors, Ribomic Inc gets an overall score of 0/5.